Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies
Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies
复制标题
DOI：
10.1016/j.bbrc.2008.09.041
复制
发表时间：
2008-11-21
影响因子：
3.1
通讯作者：
Taniguchi, Naoyuki
中科院分区：
文献类型：
--
作者：
Inohara, Hidenori;Segawa, Tatsuya;Taniguchi, Naoyuki
为了探讨血清和细针抽吸物中Galectin-3是否可作为鉴别甲状腺结节良恶性的诊断标记物，我们建立了一种酶联免疫吸附试验。我们对一系列甲状腺结节患者的细针抽吸物中的Galectin-3和另一组46例患者的血清Galectin-3进行了定量，并与甲状腺切除术后的最终组织学进行了比较。乳头状癌的相对Galectin-3值(ng/mg)定义为Galectin-3浓度(ng/ml)除以细针抽吸物中总蛋白浓度(mg/ml)，乳头状癌明显高于其他甲状腺实体。甲状腺结节患者与正常人血清Galectin-3水平差异无统计学意义。因此，相对Galectin-3的值可以独立于细胞形态而明确诊断乳头状癌，而血清Galectin-3不能作为乳头状癌的标志物。(C)2008 Elsevier Inc.保留所有权利。
in order to address whether galectin-3 in the sera and fine needle aspirates serve as a diagnostic marker distinguishing between benign and malignant thyroid nodules, we developed an enzyme-linked immunosorbent assay. We quantified galectin-3 in fine needle aspirates from a series of I IS patients with thyroid nodules and serum galectin-3 from another series of 46 patients, which were compared with final histology after thyroidectomy. Relative galectin-3 value (ng/mg), defined as galectin-3 concentration (ng/ml) divided by total protein concentration (mg/ml) in fine needle aspirates, was significantly higher in papillary carcinoma than in the other thyroid entities. There was no significant difference in serum galectin-3 level among patients with thyroid nodules and healthy individuals. Accordingly, relative galectin-3 value allows a definitive diagnosis of papillary carcinoma independent of cellular morphology, whereas serum galectin-3 does not serve as a marker for papillary carcinoma. (C) 2008 Elsevier Inc. All rights reserved.